First Patient dosed in the CaMMouflage Ph 1 Trial of CB-011 for the Treatment of R/R Multiple Myeloma April 6, 2023
Elranatamab Receives FDA and EMA Filing Acceptance with Submissions based on favorable MagnetisMM-3 trial results in patients with R/R multiple myeloma February 28, 2023
UK MHRA grants full Marketing Authorization to NEXPOVIO (selinexor), Velcade, and SVd combo for previously-treated multiple myeloma patients February 22, 2023
Nexcella Enters into U.S. GMP Manufacturing Agreement to Expand Ongoing NXC-201 Ph 1b/2 Clinical Trial to the U.S. February 22, 2023
Abecma (idecabtagene vicleucel) Reduced the Risk of Disease Progression or Death by 51% vs SoC in Earlier Lines of Therapy for R/R Multiple Myeloma in Ph 3 KarMMa-3 Study February 22, 2023
42-Patient Interim Data, with 90% ORR in R/R Multiple Myeloma at NXC-201 Therapeutic Dose from Ph 1 Expansion Trial presented February 22, 2023
China NMPA Clears IND Application for Ph 1/2 Trial of FasTCAR-T GC012F for Treatment of R/R Multiple Myeloma February 22, 2023
FDA Clears IND Application for Ph 1b/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of R/R Multiple Myeloma February 22, 2023
Kite And Arcellx Close Agreement To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma February 8, 2023
Ph 3 CARTITUDE-4 Study of CARVYKTI® (cilta-cel) meets Primary Endpoint in Patients with R/R Multiple Myeloma February 1, 2023
Data from Ph 1 UNIVERSAL Study of ALLO-715 for the Treatment of R/R Multiple Myeloma published in Nature Medicine February 1, 2023
ORIC Pharmaceuticals Announces Clinical Development Collaboration with Pfizer for ORIC-533 in Multiple Myeloma and Concurrent $25 Million Equity Investment by Pfizer January 4, 2023
FDA Approves Clinical Trial Application for BCMA CAR-T CT103A for R/R Multiple Myeloma January 4, 2023
Immix Biopharma in-licenses NXC-201, Demonstrating High CRR in Heavily Pre-Treated Multiple Myeloma (71% CR) Patients December 19, 2022
Kite And Arcellx Announce Strategic Collaboration To Co-Develop And Co-Commercialize Late-Stage Clinical CART-DdBCMA In Multiple Myeloma December 13, 2022
BLA submitted to U.S. FDA for Talquetamab for the Patients with R/R Multiple Myeloma December 12, 2022
FDA Clears IND Application for BCMA CAR-T CB-011 for the Treatment of R/R Multiple Myeloma November 30, 2022
FAILED TRIAL: Ph 3 DREAMM-3 trial of Blenrep (belantamab mafodotin) in patients with RRMM did not meet primary endpoint of progression-free survival (PFS) November 16, 2022
U.S. FDA Approves TECVAYLI (teclistamab-cqyv) for the Treatment of Patients with R/R Multiple Myeloma November 2, 2022
CAR T-Cell Therapy Targeting GPRC5D Antigen Proves Effective in First Trial in Patients with Resistant Multiple Myeloma October 5, 2022
